"Androgen Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
| Descriptor ID |
D000726
|
| MeSH Number(s) |
D06.347.065 D27.505.696.399.450.065
|
| Concept/Terms |
Anti-Androgen Effect- Anti-Androgen Effect
- Anti Androgen Effect
- Effect, Anti-Androgen
- Antiandrogen Effect
- Effect, Antiandrogen
- Antiandrogen Effects
- Effects, Antiandrogen
- Anti-Androgen Effects
- Anti Androgen Effects
- Effects, Anti-Androgen
|
Below are MeSH descriptors whose meaning is more general than "Androgen Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Androgen Antagonists".
This graph shows the total number of publications written about "Androgen Antagonists" by people in this website by year, and whether "Androgen Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 2 | 4 |
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 4 | 4 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 4 | 4 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 4 | 5 |
| 2004 | 3 | 2 | 5 |
| 2005 | 1 | 5 | 6 |
| 2006 | 6 | 1 | 7 |
| 2007 | 6 | 3 | 9 |
| 2008 | 3 | 3 | 6 |
| 2009 | 3 | 4 | 7 |
| 2010 | 7 | 7 | 14 |
| 2011 | 6 | 8 | 14 |
| 2012 | 5 | 6 | 11 |
| 2013 | 13 | 5 | 18 |
| 2014 | 5 | 2 | 7 |
| 2015 | 9 | 2 | 11 |
| 2016 | 6 | 8 | 14 |
| 2017 | 9 | 1 | 10 |
| 2018 | 4 | 4 | 8 |
| 2019 | 5 | 0 | 5 |
| 2020 | 7 | 5 | 12 |
| 2021 | 7 | 8 | 15 |
| 2022 | 3 | 10 | 13 |
| 2023 | 2 | 12 | 14 |
| 2024 | 3 | 3 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Androgen Antagonists" by people in Profiles.
-
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jul 01; 30(13):2751-2763.
-
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. JAMA Netw Open. 2024 Jul 01; 7(7):e2419966.
-
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Eur Urol Oncol. 2024 Oct; 7(5):1097-1104.
-
Functional Outcomes After Localized Prostate Cancer Treatment. JAMA. 2024 01 23; 331(4):302-317.
-
Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Curr Treat Options Oncol. 2024 01; 25(1):66-83.
-
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024 Sep; 27(3):507-519.
-
Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials. Int J Radiat Oncol Biol Phys. 2024 Jul 01; 119(3):826-831.
-
Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer. Prostate. 2024 Mar; 84(4):349-357.
-
Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment. Nat Cell Biol. 2023 Dec; 25(12):1821-1832.
-
MRI and PSMA PET/CT of Biochemical Recurrence of Prostate Cancer. Radiographics. 2023 12; 43(12):e230112.